Olema Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M |
| Operating expenses | $178.7M | $142.3M | $105.0M | $107.0M | $71.5M |
| Cash from operations | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M |
| Capital expenditure | — | $159,000 | — | $363,000 | $1.6M |
| Free cash flow | — | -$104.5M | — | -$82.4M | -$52.3M |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M |
Shares outstanding 87.3M · Free float 68.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.